Dr Lisa Crowley

BSc Biochemistry, PhD Medicine and Health

Research Officer


Prostate Cancer and Chemotherapy Improvement

The overall aim of the project is to improve the therapeutic outcome for aggressive prostate cancer by understanding cell death pathways. The treatments focus on chemotherapy and immunotherapy.

Stillbirth Prevention Translating Research into Practice

As clinical project co-ordination I am bringing the best available evidence into practice. My projects are currently based on implementing new hospital policies and guidelines as well in the area of pregnancy and newborns across Australia. Central to my research to improve health care delivery, is liaising with clinicians and with patients. 

Improving the chemotheraputic and immuotherapy treatments available for prostate cancer.

About me

Prior to her work in Australia, Lisa obtained her degree in Biochemistry at University College Cork, Ireland. She went on to complete her PhD in Medicine and Health with the research organization Cork Cancer Research Centre. During her PhD Lisa investigated the effects of cell death on chemotherapy resistance in leukemia. Her research was centered on the manipulation of Autophagy to improve the chemotherapeutic outcome of treatments in CML and Ph+ALL. In 2011 Lisa began working with Mater Research on prostate cancer and cell death. For the past three years Lisa’s work has concentrated on improvement of treatment outcomes for advanced stages prostate cancer. Her research was aimed at identifying the most effective combinations of new and old chemotherapeutics. She also focused on the use of immunotherapy in combination with new generation chemotherapy. During her time at Mater Research Lisa has become an active member on a number of committees including the ECR committees and TRI user groups. She is currently halving her time between cancer research here at TRI and a clinical based project in the area of stillbirth prevention at the Mater Hospital. Her ultimate goal is to promote more effective treatments within the hospital environments through effective translation of research into practice.


     Crowley, L. C., O’Donovan T.R., Nyhan M.J. and McKenna, S. L. (2013) Pharmacological inherent anti-autophagic activity improves the cytotoxicity of imatinib Oncology Reports.  (epub)

     Elzinga BM* and Nyhan MJ*, Crowley LC, O'Donovan TR, Cahill MR, et al. (2013) Induction of autophagy by imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein. American Journal of Hematology. * joint first authors

 Nyhan MJ*, O'Donovan TR*, Elzinga B, Crowley LC, O'Sullivan GC, et al. (2012) The BH3 mimetic HA14-1 enhances 5-fluorouracil-induced autophagy and type II cell death in oesophageal cancer cells. Br J Cancer 106: 711-718. * joint first authors

 Crowley, L. C., Elzinga, B. M., O'Sullivan, G. C. and McKenna, S. L. (2011), Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment. Am. J. Hematol., 86: 38–47. doi: 10.1002/ajh.21914 

Research fields

Cell death, Cancer Treatments, Leukeamia, Prostate Cancer, Clinical Research, Stillbirth, Mothers and Babies